In lupus nephritis, the benefit of rituximab monotherapy, as opposed to rituximab plus cyclophosphamide combination therapy, remains uncertain: comment on the article by Sfikakis et al.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples